Australian biotech giant Microba has made an alliance with Macrogen to develop microbiome research services for the offshore market. An MOU has got signed at the Macrogen Headquarters in Seoul on 14 March 2019 defining all the partnership terms and condition. Through this MOU, Macrogen and Microba will establish a close cooperation system. With this partnership, they will try to penetrate into the microbiome market of Korea and other nations
Macrogen is a significant Korean company which has a market capitalization of 350m USD and annual revenues touching 100m USD. The Chairman and Founder Dr. Seo is an eminent scientist. On the other part, Microba is a globally known genomics company with exclusive technology platform using shotgun metagenomics sequencing to accurately characterize the millions of micro-organisms that inhabit the large intestine known as the gut genome.
“Microba is a company with world-leading technology in the microbiome field, which is one of the fastest-growing industries,” says Kap-Seok Yang, CEO of Macrogen, adding “Partnership between our companies will generate great synergy to develop and launch highly reliable services to global markets such as the USA, Europe, Japan, and Singapore, starting from the Korean market.
On the other hand, Blake Wills, CEO of Microba has also expressed his pleasure to work with Macrogen. He has also said that Macrogen is a well-known company for its world-class genetics analysis capacity and its vast experience in data analysis. He is also hopeful that both the companies will work closely to advance microbiome analysis technology as well as launching various services in the Direct to Consumer, Research and Clinical markets.
